NCT06468215Recruiting
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- First submitted
- 5 Jun 2024
- Start date
- 21 Jun 2024
- Primary completion date
- Jul 2028
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Endometrial cancer, Childhood cancers
- NCT number
- NCT06468215
What you commit to
- Study type: Interventional
- Planned participants: 16
- From 21 Jun 2024 to the primary completion date, Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have contraindications for conservative treatment or drug use.
Other illness
- Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer
- There are malignant tumors in other systems.
Other
- The tumor has invaded the muscle layer.
- FIGO (2009) stage IB or higher.
- Have been judged by the researcher to be unsuitable for childbearing.
Who the study is looking for
- Endometrioid adenocarcinoma G2, diagnosis by pathological.
- The lesion is limited to the endometrium.
- FIGO (2009) staging is IA.
- Age less than 45.
- Strongly request to preserve fertility.
- Sign informed consent.
Age in the registry: - to 45 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.